Concepedia

Luis Fein

LF

Statistics

Publications

38

Citations

11.4K

H-Index

25

Active since

1997

Affiliations

Instituto de Oncología de Rosario(Current)

Institut Gustave Roussy

Memorial Sloan Kettering Cancer Center

Dana-Farber Cancer Institute

National Cancer Center Hospital East

Luis Fein is an author at Instituto de Oncología de Rosario specializing in medicine, oncology, and pharmacology.

ORCID

Publications per year

1997–2024

38

Publications

38

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.3K citations · Full text

, , +15

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

Karim Fizazi, NamPhuong Tran, Luis Fein et al. · New England Journal of Medicine · 2017 · 2.2K citations · Full text

, , +15

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

Andrea Wang‐Gillam, Chung‐Pin Li, G. Bodoky et al. · The Lancet · 2015 · 1.2K citations

, , +16

Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial

Karim Fizazi, NamPhuong Tran, Luis Fein et al. · The Lancet Oncology · 2019 · 813 citations · Full text

, , +16

Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT

Stephen Chia, William J. Gradishar, L. Mauriac et al. · Journal of Clinical Oncology · 2008 · 533 citations · Full text

, , +15

1–5 of 38